Try GOLD - Free
Maharashtra, powerhouse of Indian pharma industry
Chronicle Pharmabiz
|September 18, 2025
MAHARASHTRA, particularly the Mumbai-Pune corridor, is indisputably the powerhouse of the Indian pharmaceutical industry.
Contributing approximately 25-30 per cent of India's total pharmaceutical output and housing over 40 per cent of the nation's pharmaceutical R&D centres, the state is a critical hub for manufacturing, innovation, and exports. However, this preeminent position is challenged by intense domestic competition, infrastructural bottlenecks, environmental concerns, and a rapidly evolving global regulatory landscape.
Region-wise distribution of pharma industry
The pharmaceutical industry in Maharashtra is strategically concentrated in key regional clusters, each with a distinct role. The Mumbai Metropolitan Region (MMR), encompassing Mumbai, Thane, Navi Mumbai, and Palghar, remains the historical and corporate heartland.
It hosts the headquarters of industry giants like Cipla, Sun Pharma, and multinational corporations such as Pfizer and GSK, serving as a central hub for corporate functions, regulatory affairs, marketing, and R&D. While still a dominant centre for formulating complex drugs and vaccines, its high operational costs and space constraints are gradually shifting manufacturing focus to other regions.
According to the Maharashtra Industrial Development Corporation (MIDC), the Mumbai and Konkan region continues to account for a significant, though dynamically changing, portion of the state's pharmaceutical units.
In contrast, Pune has solidified its status as the emerging "Pharma & Biotech Capital" of India. The region, including Pune city, Pimpri-Chinchwad, and Hinjawadi, is an epicentre of innovation, hosting a dense cluster of R&D centres, CRAMS players, and biotech startups, bolstered by world-class institutions like the National Chemical Laboratory and the Serum Institute of India. A report by the India Brand Equity Foundation (IBEF) highlights its prominence, noting over 800 manufacturing units in the broader region.
This story is from the September 18, 2025 edition of Chronicle Pharmabiz.
Subscribe to Magzter GOLD to access thousands of curated premium stories, and 10,000+ magazines and newspapers.
Already a subscriber? Sign In
MORE STORIES FROM Chronicle Pharmabiz
Chronicle Pharmabiz
Home-grown CAR-T cell therapies gaining ground
INDIAN biotech and pharmaceutical companies are actively working on innovative solutions to make CART cell therapy both accessible and cost-effective.
4 mins
November 27, 2025
Chronicle Pharmabiz
NPPA extends price fixation on orthopaedic implants for 1 year
IN a move that will disappoint the industry, the National Pharmaceutical Pricing Authority (NPPA) has extended the ceiling price fixation it imposed on orthopaedic knee implants for knee replacement system for one more year.
1 mins
November 27, 2025
Chronicle Pharmabiz
FICCI envisages it's Smart AAMs to boost healthcare
In line with the Central Government's vision of comprehensive primary healthcare, FICCI Swasth Bharat Task Force has undertaken a transformative initiative titled 'Smart Ayushman Arogya Mandirs-AAMs' (earlier called Health & Wellness Centres) aimed at strengthening the primary healthcare delivery system across India.
1 min
November 27, 2025
Chronicle Pharmabiz
DoP asked to bring policy for affordable drug pricing
THE Parliamentary Panel on Chemicals and Fertilisers has recommended to the Department of Pharmaceutical (DoP) to take steps to come out with a pharmaceutical policy with thrust to provide both scheduled and nonscheduled formulations at affordable prices.
1 mins
November 27, 2025
Chronicle Pharmabiz
Ramaiah emphasises need for bone health and osteoporosis diagnosis
RAMAIAH Memorial Hospital (RMH), a multi-superspecialty quaternary care hospitals emphasises on bone health and osteoporosis diagnosis. It calls for timely screening and diagnosis through the new and advanced DXA scanner with superior and accurate test results.
2 mins
November 27, 2025
Chronicle Pharmabiz
Nathealth calls for action in 2026-27 Union Budget
NATHEALTH has submitted its budget 2026-27 recommendations to the Union government, outlining a roadmap to strengthen healthcare delivery, foster innovation, and expand insurance and preventive coverage.
1 mins
November 27, 2025
Chronicle Pharmabiz
Hotspots & growth opportunities in biomanufacturing
THE Indian bioeconomy has grown from US$ 10 billion in 2014 to US$ 165.7 billion in 2024, and is likely reach US$ 300 billion by 2030.
3 mins
November 27, 2025
Chronicle Pharmabiz
Omega Hospitals acquires Cytecare Hospitals
Morgan Stanley PE backed Hyderabad-based Omega Hospitals has acquired Cytecare Hospitals, a leading cancer care hospital in Bengaluru.
2 mins
November 27, 2025
Chronicle Pharmabiz
Devices sector hails withdrawal of QCOs
THE medical devices manufacturers industry in the country has welcomed the Central government's decision to withdraw multiple Quality Control Orders (QCOs) imposed on essential raw materials across various industries, including the medical devices sector.
1 min
November 27, 2025
Chronicle Pharmabiz
'There is urgent need for tech-focused regulatory approach for med devices'
THE Indian healthcare industry has evolved at a breakneck pace, but its regulatory framework has struggled to keep up to its speed of development.
2 mins
November 27, 2025
Listen
Translate
Change font size
